**1** Investigating pleiotropy between depression and autoimmune diseases using the UK Biobank.

- 2 Kylie P Glanville<sup>1</sup>, Jonathan R I Coleman<sup>1,2</sup>, Paul F O'Reilly<sup>3</sup>, \*James Galloway<sup>4</sup>, \*Cathryn M
- 3 Lewis<sup>1,2,5</sup>
- 4 \*Contributed equally and share senior authorship.
- 5 1. Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology &
- 6 Neuroscience, King's College London, London, GB
- 7 2. NIHR Biomedical Research Centre, South London and Maudsley NHS Trust, King's College
- 8 London, London, GB
- 9 3. Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, New York, NY, US
- 10 4. Department of Inflammation Biology, King's College London, London, GB
- 11 5. Department of Medical & Molecular Genetics, King's College London, London, GB
- 12
- 13 Address correspondence to Kylie P. Glanville, kylie.glanville@kcl.ac.uk; Social, Genetic and
- 14 Developmental Psychiatry Centre; Institute of Psychiatry, Psychology & Neuroscience; King's
- 15 College London, de Crespigny Park, London SE5 8AF; UK.

# 16 Abstract

Background: Epidemiological studies have shown increased comorbidity between depression and autoimmune diseases. The mechanisms driving the comorbidity are poorly understood, and a highly powered investigation is needed to understand the relative importance of shared genetic influences. We investigated the evidence for pleiotropy from shared genetic risk alleles between these traits in the UK Biobank (UKB).

22 **Methods:** We defined autoimmune and depression cases using information from hospital 23 episode statistics, self-reported conditions and medications, and mental health questionnaires. 24 Pairwise comparisons of depression prevalence between autoimmune cases and controls, and 25 vice-versa, were performed. Cross-trait polygenic risk score (PRS) analyses were performed to 26 test for pleiotropy, i.e. testing whether PRS for depression could predict autoimmune disease 27 status, and vice-versa.

28 **Results:** We identified 28k cases of autoimmune diseases (pooling across 14 traits) and 324k autoimmune controls, and 65k cases of depression and 232k depression controls. The prevalence 29 30 of depression was significantly higher in autoimmune cases compared to controls, and vice-versa. 31 PRS for myasthenia gravis and psoriasis were significantly higher in depression cases compared 32 to controls (p <  $5.2 \times 10^{-5}$ ,  $R^2$  <= 0.04%). PRS for depression were significantly higher in 33 inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis and type 1 diabetes cases compared to controls ( $p < 5.8 \times 10^{-5}$ ,  $R^2$  range 0.06% to 0.27%), and lower in coeliac 34 disease cases compared to controls ( $p < 5.4 \times 10^{-7}$ ,  $R^2$  range 0.11% to 0.15%). 35

- 36 Conclusions: Consistent with the literature, depression was more common in individuals with
- 37 autoimmune diseases compared to controls, and vice-versa, in the UKB. PRS showed some
- 38 evidence for involvement of shared genetic factors, but the modest  $R^2$  values suggest that shared
- 39 genetic architecture accounts for only a small proportion of the increased risk across traits.

### 40 Introduction

41 There is evidence that individuals with a history of autoimmune disease are at greater risk for developing depression<sup>1-4</sup>, and that a history of depression increases risk for developing 42 autoimmune diseases<sup>5,6</sup>. The mechanisms driving the bi-directional relationship are poorly 43 44 understood, but one contributory factor may be that these diseases share biological pathways. We and others have shown that there is no strong evidence for the involvement of Human 45 46 Leukocyte Antigen (HLA) alleles in risk for depression, suggesting that the Major 47 Histocompatibility Complex (MHC) does not harbor shared risk for depression and autoimmune diseases<sup>6-8</sup>. However, genetic risk for autoimmune diseases occurs across the genome<sup>9</sup>, and 48 49 pleiotropic effects outside the MHC may be involved in shared risk for depression and 50 autoimmune diseases.

51 Few studies have investigated evidence for genome-wide pleiotropy between depression and autoimmune diseases. Euesden, et al.<sup>10</sup> found no evidence for association between polygenic risk 52 scores (PRS) for depression and risk for rheumatoid arthritis, or vice-versa. The Psychiatric 53 Genomics Consortium (PGC) indicated no evidence for significant genetic correlations (rG) 54 55 between depression and nine autoimmune diseases (after multiple testing correction across 221 56 traits in total); the strongest correlation observed was between depression and inflammatory bowel disease (rG = .07, uncorrected p = .01)<sup>11</sup>. Recently, Liu, et al.<sup>6</sup> found no association 57 between PRS for mental health disorders and risk for autoimmune diseases, and only a weak 58 59 association between PRS for autoimmune diseases and risk for mental health disorders.

medRxiv preprint doi: https://doi.org/10.1101/2020.12.08.20242495; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

60 We extend previous work, leveraging the UK Biobank (UKB) to test for pleiotropy between 61 depression and autoimmune diseases with PRS methodology. Given the challenge of reliably 62 defining complex disease traits using large-scale data, we take two approaches to defining 63 autoimmune diseases and depression. We classified liberally-defined cases, based on a single 64 item endorsing diagnosis with an autoimmune disease, and strictly-defined cases, based on multiple items. We use this approach to identify individuals affected by any of fourteen 65 66 autoimmune or autoinflammatory traits - collectively referred to as autoimmune diseases 67 throughout. We take a similar approach to classifying depression by requiring a greater number of endorsements in strictly-defined cases than liberally-defined cases. Liberally-defined cases 68 increase the sample size, while strictly-defined cases will reduce the rate of misclassification. We 69 70 perform cross-trait PRS analyses, testing for association between PRS for autoimmune diseases 71 and depression, and vice-versa. Motivated by the observation of sex-dependent genetic correlations between schizophrenia and autoimmune diseases<sup>12</sup>, and by higher prevalence in 72 73 females of both depression and autoimmune diseases, we stratified PRS analyses by sex. Our study is one of the largest to explore pleiotropy between depression and autoimmune diseases 74 75 and elucidates the contribution of shared genetic influences to the observed comorbidity.

# 76 Methods

#### 77 Participants

The UKB is a prospective health study of 500,000 individuals in the United Kingdom. Participants 78 79 were identified through NHS patient registers if they were aged 40-69 during the recruitment 80 phase (2006-2010) and living in proximity to an assessment centre. Participants attended a baseline assessment and contributed health information via touchscreen questionnaires and 81 verbal interviews<sup>13</sup>. Subsets of participants completed repeat assessments: instance 1) n = 20,335 82 83 between 2012-2013; instance 2) n = 42,961 (interview) and n = 48,340 (touchscreen) in 2014; and instance 3) n = 2,843 (interview) and n = 3,081 (touchscreen) in 2019. Participant data are 84 linked to Hospital Episode Statistics (HES) containing information on episodes of inpatient care. 85 86 Episodes are coded at admission using the International Classification of Diseases, 10<sup>th</sup> Revision<sup>14</sup> 87 (ICD-10). Inpatients are assigned one primary code (reason for admission) and a variable number 88 of secondary codes. Additional data are available for psychiatric phenotyping, including an online Mental Health Questionnaire (MHQ) completed by 157,366 participants in 2017<sup>15</sup>. The UKB 89 90 received ethical approval from the North West - Haydock Research Ethics Committee (reference 16/NW/0274). Participants provided electronic signed consent at recruitment<sup>13</sup>. 91

#### 92 Autoimmune phenotyping

93 Guided by studies that investigated the epidemiological relationship between autoimmune 94 diseases and depression<sup>1,5</sup> we identified cases for fourteen autoimmune diseases: pernicious

anemia (PA), autoimmune thyroid disease (ATD), type 1 diabetes (T1D), multiple sclerosis (MS),
myasthenia gravis (MG), coeliac, inflammatory bowel disease (IBD; includes crohn's disease and
ulcerative colitis), psoriasis, ankylosing spondylitis (AS), polymyalgia rheumatica/giant cell
arteritis (PR/GCA), psoriatic arthritis (PsA), rheumatoid arthritis (RA), sjögren syndrome (SS), and
systemic lupus erythematosus (SLE).

100 Two sources of information were used to define autoimmune cases and controls. (1) HES: primary 101 and secondary ICD-10 diagnoses recorded between April 1997 to October 2016 were identified 102 from the UKB Data Portal Record Repository. (2) Verbal interview: participants' responses at 103 baseline or instance 1 or 2 to determine self-endorsed medical conditions (past and current) and 104 self-endorsed prescription medications (current). ICD-10 codes, self-endorsed conditions and 105 medications used to define each autoimmune disease are listed in the Supplementary Material.

106 We took two approaches to defining autoimmune cases (Figure 1). To increase sample size, we 107 created 'possible' cases, comprising participants with an ICD-10 diagnosis or a self-endorsed 108 condition. To increase validity, we used multiple observations to create 'probable' cases. 109 Participants were coded as probable cases if at least two of ICD-10 diagnosis, self-endorsed 110 condition or medication were observed. More than one ICD-10 diagnosis for the corresponding 111 autoimmune disease was also sufficient. A set of autoimmune controls was defined from 112 participants with no ICD-10 diagnoses, self-endorsed conditions or medications for all fourteen 113 autoimmune diseases. A single set of controls was used for all autoimmune diseases, given the 114 known comorbidity between them.






Figure 1: Autoimmune phenotyping approach. Cases are included in possible or probable if they fall within a
shaded area. Autoimmune medication was used as a confirmatory, but not a primary source of information,
because several medications are not disease-specific.

119

### **120** Depression phenotyping

We created two depression case groups: strictly-defined cases termed 'stringent depression' and liberally-defined cases termed 'any depression'. We have previously shown that SNP-based heritability increases with multiple endorsements of depression<sup>16</sup>. We therefore classified 'stringent depression' as participants endorsing at least three of the following depression measures: ICD-10 diagnoses (F32-F33.9); self-reported depression; self-reported antidepressant usage; single or recurrent depression (defined by Smith, et al.<sup>17</sup> from responses to a questionnaire completed at baseline by 172,751 participants); or answered 'yes' to the

questionnaire: "Have you ever seen a GP/psychiatrist for nerves, anxiety, tension ordepression?".

We classified 'any depression' as participants who endorsed two or more depression measures, or if they met criteria for lifetime depression in the Composite International Diagnostic Interview (CIDI) assessed in the MHQ<sup>15</sup>. We classify cases defined from CIDI alone as 'any depression' not as 'stringent depression' because we previously observed lower SNP-based heritability in this group ( $h^{2}_{SNP} = 11\%$ , SE = 0.008) compared to cases defined by three or more non-CIDI measures of depression ( $h^{2}_{SNP} = 19\%$ , SE = 0.018)<sup>16</sup>.

Depression cases were screened for schizophrenia and bipolar according to any indication: ICD-10 diagnoses (F20-29, F30-31.9, F34-39); self-endorsed conditions (schizophrenia, mania, bipolar disorder or manic depression) or self-endorsed antipsychotic usage reported at baseline or instance 1 or 2; Bipolar Type I (Mania) or Bipolar Type II (Hypomania) according to the criteria adopted by Smith, et al.<sup>17</sup>; or indications of psychosis endorsed in the MHQ. A single set of depression controls was defined from participants who did not meet the criteria for depression, schizophrenia or bipolar.

Derivation of depression, schizophrenia and bipolar indications can be found in Supplementary
 Materials from our previous publication<sup>16</sup>.

### 145 Genetic quality control (QC)

The UKB performed preliminary QC on genotype data assayed for all participants<sup>13</sup>. Using genetic 146 147 principal components (PCs) provided by the UKB, we performed 4-means clustering on the first 148 two PCs to identify and retain individuals of European ancestry. QC was then performed using PLINK v1.9<sup>18</sup> to remove: variants with missingness > 0.02 (before individual QC), individuals with 149 150 missingness > 0.02, individuals whose self-reported sex was discordant from their genetic sex, 151 variants with missingness > 0.02 (after individual QC), variants departing from Hardy-Weinberg 152 Equilibrium (p < 10e-8), and variants with minor allele frequency (MAF) < 0.01. Relatedness 153 kinship estimates provided by the UKB were used to identify pairs of related individuals (KING r<sup>2</sup> > 0.044)<sup>19</sup> and the GreedyRelated<sup>20</sup> algorithm used to remove one individual from each pair, 154 preferentially retaining individuals that survived QC. FlashPCA2<sup>21</sup> was used to generate PCs for 155 156 the sub-set of individuals of European ancestry surviving QC. PRS analyses were performed using 157 genotype data.

#### **158** Statistical analyses

We summarised sociodemographic data taken at baseline assessment: age, sex, socio-economic status (SES), body mass index (BMI) and current smoking status. We tested for significant differences in sociodemographic variables between cases and controls using Welch Two Sample t-tests in R v3.6<sup>22</sup>. We tested for significant differences in: 1) the prevalence of depression in autoimmune cases compared to autoimmune controls, and 2) the prevalence of autoimmune diseases in depression cases compared to depression controls. These tests were performed for

both probable/possible autoimmune cases and stringent/any depression, using 2-sample tests
for equality of proportions in R v3.6<sup>22</sup>.

**167** Summary statistics for autoimmune diseases and depression

168	We searched PubMed and the NHGRI-EBI GWAS Catalog
169	(https://www.ebi.ac.uk/gwas/downloads/summary-statistics) for the latest genome-wide
170	association study (GWAS) with publicly-available summary statistics, using the name of the
171	relevant trait (and "GWAS" or "genome-wide association study" on PubMed). We identified
172	summary statistics for eight of the fourteen autoimmune diseases: coeliac <sup>23</sup> , IBD <sup>24</sup> , MS <sup>25</sup> , MG <sup>26</sup> ,
173	psoriasis <sup>27</sup> , PsA <sup>28</sup> , RA <sup>29</sup> , and SLE <sup>30</sup> (Table 1). For MG, psoriasis and PsA, we contacted the authors
174	of the primary GWASs directly to obtain access. Summary statistics from GWAS using the
175	Immunochip were excluded as it does not provide genome-wide coverage. For Major Depressive
176	Disorder (MDD), we used summary statistics from Wray, et al. <sup>11</sup> , excluding UKB.

177 Table 1: GWAS summary statistics used to generate polygenic risk scores.

Trait	Year	Ancestry	Assembly	Cases	Controls
Coeliac Disease	2010	European	GRCh37/hg19	4,533	10,750
Inflammatory Bowel Disease	2015	European	GRCh37/hg19	12,882	21,770
Multiple Sclerosis	2011	European	GRCh37/hg19	9,772	17,376
Myasthenia Gravis	2015	European	GRCh37/hg19	1,032	1,998
Psoriasis	2017	European	GRCh37/hg19	19,032	286,769
Psoriatic Arthritis	2018	European	GRCh37/hg19	1,430	1,417
Rheumatoid Arthritis	2014	European	GRCh37/hg19	14,361	43,923
System Lupus Erythematosus	2015	European	GRCh37/hg19	7,219	15,991
Major Depressive Disorder	2018	European	GRCh37/hg19	116,404	314,990

#### **179** Polygenic risk score (PRS) analyses

PRS analyses were conducted using the PRSice-2 software<sup>31</sup>. QC was performed on summary statistics to remove variants within the MHC (28.8 to 33.7 Mb), and default clumping settings were applied in PRSice-2 to remove variants in linkage disequilibrium ( $r^2 > 0.1$ ) with the lead variant within a 250kb region.

To validate our phenotyping approach, we tested for association between PRS for eight autoimmune diseases and case-control status for the corresponding diseases (possible and probable cases), and between PRS for MDD and case-control status for depression (any and stringent).

To investigate pleiotropy between autoimmune diseases and depression we performed crosstrait analyses, testing for association between 1) PRS for eight autoimmune diseases and casecontrol status for depression (any and stringent cases); and 2) PRS for MDD and case-control status for fourteen autoimmune diseases (possible and probable cases). To test for sex-specific effects, we performed cross-trait analyses in males and females separately.

For each test, PRS constructed at eight p-value thresholds ( $P_T$ ; 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 and 1.0) were regressed on case-control status using logistic regression, adjusting for the following covariates: six PCs, genotyping batch, and assessment centre (n=128 variables). We report p-values at the optimal  $P_T$  for each test of association. To control for multiple testing across  $P_T$  (x8), and across tests of association (autoimmune PRS (x8) predicting any/stringent depression (x2) in men and women (x2), n=32; and MDD PRS predicting possible/probable (x2) autoimmune

199 diseases (x14) in men and women (x2), n=56), a Bonferroni correction was applied to give a p-200 value threshold for significance of  $7.1 \times 10^{-5}$  (0.05/704 tests, 704 = 8\*(32+56)). Where sex-specific 201 associations were observed, sensitivity analyses were conducted to account for different sample 202 sizes between sexes. We tested for interactions between sex and PRS (at the optimal  $P_{\rm T}$  from sex-203 specific tests) in the full sample (Phenotype ~ sex + PRS + sex\*PRS + covariates). We report  $R^2$ 204 estimates transformed to the liability scale using the following population prevalences for outcome traits: PA=0.1%<sup>32</sup>, ATD=2%<sup>33</sup>, T1D=0.3%<sup>34</sup>, MS=0.1%<sup>25</sup>, MG=0.02%<sup>35</sup>, coeliac=1%<sup>23</sup>, 205 IBD=0.5%<sup>24</sup>, psoriasis=2%<sup>36</sup>, AS=0.55%<sup>37</sup>, PR/GCA= 0.85%<sup>38</sup>, PsA=0.5%<sup>28</sup>, RA=1%<sup>39</sup>, SS=0.7%<sup>40</sup>, 206 SLE=0.1%<sup>41</sup> and MDD=15%<sup>11</sup>. 207

AVENGEME<sup>42</sup> was used to estimate power to detect cross-trait PRS associations, assuming 208 209 varying degrees of genetic correlation (rG) between corresponding traits (rG 0.01 to 0.5). Power 210 was estimated for cross-trait analyses where summary statistics for both traits were available 211 (i.e. eight autoimmune disorders and MDD) so that SNP-based heritability (required for power 212 calculations in AVENGEME) could be estimated using Linkage Disequilibrium Score Regression (LDSC v1.0.1)<sup>43</sup> (Supplementary Figure 1). Power was estimated using PRS at the optimal  $P_{T}$ 213 214 identified in cross-trait association tests, and liberally-defined sample sizes. Parameters used to 215 estimate power are in Supplementary Tables 1 and 2.

LDSC v1.0.1<sup>43</sup> was used to estimate rG between the UKB depression phenotypes ('any' and 'stringent') and autoimmune diseases with publicly-available summary statistics. To robustly apply LDSC, we limited the autoimmune diseases to those with sample sizes above 5k in the

- 219 primary GWAS (coeliac<sup>23</sup>, IBD<sup>24</sup>, MS<sup>25</sup>, psoriasis<sup>27</sup>, RA<sup>29</sup>, and SLE<sup>30</sup>). To control for multiple testing
- across traits, a Bonferroni correction was applied to give a p-value threshold for significance of
- 221 4.1x10<sup>-3</sup> in rG analyses (0.05/12 tests).

# 222 Results

223	A total of 28,479 individuals were identified as possible cases across fourteen autoimmune
224	diseases, and a sub-set of 16,824 (59.1%) met the stringent criteria for probable cases (refer
225	Supplementary Material for representation of the overlap between criteria used to define cases).
226	65,075 individuals met the criteria for any depression, 14,625 of whom met the criteria for
227	stringent depression. Sociodemographic characteristics for autoimmune and depression cases
228	and controls are summarised in Table 2. Overall, autoimmune and depression case groups
229	contained a higher proportion of females, had lower SES, higher smoking prevalence, and higher
230	BMI than their respective control groups, (N = $324,074$ autoimmune controls, N = $232,552$
231	depression controls, all p-values < $5 \times 10^{-21}$ in pairwise comparisons).

Table 2: Sociodemographic information for autoimmune and depression cases and controls. Pop. Prev. = population prevalence estimate. UKB Prev. = prevalence of cases

in the UKB as a proportion of autoimmune/depression controls. TDI = Townsend Deprivation Index; negative scores indicate less deprivation. SD = standard deviation.

		Pop. Prev.	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)	Count	UKB Prev.	Mean age (SD)	Female (%)	TDI (SD)	Current smoker (%)	Mean BMI (SD)
Autoin	nmune Diseases (system/disease)					Possib	le						Probable			
Blood	Pernicious Anemia	0.10%	1,555	0.48%	58.9 (7.61)	71%	-0.85 (3.19)	13%	28.0 (5.55)	423	0.13%	60.1 (7.19)	72%	-0.99 (3.23)	12%	28.5 (5.34)
rine	Autoimmune Thyroid Disease	2.00%	859	0.26%	56.8 (7.75)	85%	-1.11 (3.05)	15%	27.4 (5.11)	607	0.19%	57.0 (7.64)	86%	-1.06 (3.03)	16%	27.8 (5.21)
Endocrine system	Type 1 diabetes	0.30%	2,751	0.84%	58.3 (7.80)	42%	-0.46 (3.39)	13%	30.1 (6.08)	2,292	0.70%	58.0 (7.85)	43%	-0.50 (3.39)	12%	29.9 (6.07)
Nervous system	Multiple Sclerosis	0.10%	1,683	0.52%	55.4 (7.52)	73%	-1.45 (3.01)	16%	26.9 (5.08)	1,154	0.35%	55.5 (7.45)	73%	-1.33 (3.06)	17%	26.9 (5.27)
Nerv syst	Myasthenia Gravis	0.02%	234	0.07%	59.2 (7.39)	56%	-0.94 (3.27)	11%	29.0 (5.44)	147	0.05%	60.1 (7.09)	48%	-1.06 (3.32)	12%	29.3 (5.18)
tive	Coeliac	1.00%	2,364	0.72%	57.8 (7.79)	67%	-1.49 (2.99)	7%	25.8 (4.57)	1,260	0.39%	58.4 (7.66)	68%	-1.42 (3.03)	7%	25.8 (4.60)
Digestive system	Inflammatory Bowel Disease	0.50%	5,105	1.55%	57.4 (7.92)	51%	-1.27 (3.10)	10%	27.3 (4.70)	3,538	1.08%	57.3 (7.98)	50%	-1.28 (3.07)	9%	27.2 (4.63)
Skin	Psoriasis	2.00%	5,459	1.66%	56.8 (8.01)	46%	-1.05 (3.22)	15%	28.4 (5.17)	2,759	0.84%	57.1 (8.04)	42%	-0.90 (3.28)	16%	28.7 (5.26)
pue	Ankylosing Spondylitis	0.55%	1,344	0.41%	57.9 (7.47)	38%	-1.02 (3.21)	13%	27.8 (4.80)	413	0.13%	57.4 (7.57)	26%	-1.06 (3.22)	12%	27.9 (4.85)
Musculoskeletal system and connective tissue	Polymyalgia Rheumatica/GCA	0.85%	1,627	0.50%	63.1 (5.16)	67%	-1.70 (2.79)	9%	28.3 (5.08)	898	0.28%	63.7 (4.58)	68%	-1.67 (2.75)	9%	28.4 (5.24)
tal sys ve tiss	Psoriatic Arthritis	0.50%	1,107	0.34%	56.6 (7.48)	50%	-1.16 (3.18)	11%	29.0 (5.43)	779	0.24%	56.6 (7.52)	51%	-1.06 (3.23)	11%	29.3 (5.59)
skelet	Rheumatoid Arthritis	1.00%	6,360	1.92%	59.5 (7.06)	67%	-0.91 (3.29)	13%	28.5 (5.53)	3,451	1.05%	59.6 (7.01)	70%	-1.08 (3.18)	12%	28.2 (5.50)
isculo cor	Sjögren Syndrome	0.70%	647	0.20%	59.3 (7.10)	90%	-1.20 (3.03)	6%	27.1 (5.72)	389	0.12%	59.2 (7.26)	89%	-1.19 (3.10)	7%	27.0 (5.55)
Mu	Systemic Lupus Erythematosus	0.10%	624	0.19%	56.7 (8.18)	84%	-1.02 (3.21)	14%	27.3 (5.65)	362	0.11%	56.6 (8.00)	86%	-0.99 (3.15)	14%	27.3 (5.82)
	Any Autoimmune Disease	NA	28,479	8.08%	58.1 (7.73)	58%	-1.11 (3.17)	12%	27.9 (5.28)	16,824	4.94%	58.1 (7.73)	57%	-1.10 (3.17)	12%	28.0 (5.34)
	Autoimmune Controls	NA	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)	324,074	NA	56.4 (8.06)	52%	-1.50 (2.98)	10%	27.2 (4.64)
Depression						Any							Stringent			
	Depression	15%	65,075	21.86%	55.4 (7.86)	67%	-1.09 (3.14)	13%	27.8 (5.32)	14,625	5.92%	56.1 (7.88)	67%	-0.58 (3.35)	19%	28.9 (5.77)
	Depression Controls	NA	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)	232,552	NA	57.1 (8.10)	47%	-1.65 (2.89)	9%	27.2 (4.53)

The prevalence of any depression was significantly higher in autoimmune cases compared to autoimmune controls ( $p = 6x10^{-177}$  for possible cases of any autoimmune disease versus controls,  $p = 2x10^{-124}$  for probable cases of any autoimmune disease versus controls). The prevalence of stringent depression was significantly higher in autoimmune cases compared to autoimmune controls ( $p = 3x10^{-129}$  $^{207}$  for possible cases of any autoimmune disease versus controls,  $p = 6x10^{-163}$  for probable cases of any autoimmune disease versus controls,  $p = 6x10^{-163}$  for probable cases of any autoimmune disease versus controls) (Table 3).

Table 3: Prevalence of depression within autoimmune cases compared to autoimmune controls, stratified by possible/probable for autoimmune diseases, and any/stringent for depression cases. P-values from pairwise comparisons of depression prevalence in autoimmune cases compared to autoimmune controls are shown in brackets.

	Depression prevalence in autoimmune traits									
	An	y depressi	on prev	alence	Stringent depression prevalence					
A	Autoimmune Trait				Probable Autoimmune		Possible Autoimmune		obable bimmune	
	Autoimmune Controls		20	.6%			5.	1%		
	Any Autoimmune Disease	28.9%	(6x10 <sup>-177</sup> )	29.5%	(2x10 <sup>-124</sup> )	10.8%	(3x10 <sup>-207</sup> )	11.5%	(6x10 <sup>-163</sup> )	
Blood	Pernicious Anemia	35.8%	(4x10 <sup>-36</sup> )	33.7%	(4x10 <sup>-8</sup> )	15.2%	(1x10 <sup>-39</sup> )	16.6%	(4x10 <sup>-15</sup> )	
Fada airea austarra	Autoimmune Thyroid Disease	35.1%	(6x10 <sup>-19</sup> )	34.7%	(6x10 <sup>-13</sup> )	13.7%	(1x10 <sup>-16</sup> )	13.4%	(3x10 <sup>-11</sup> )	
Endocrine system	Type 1 diabetes	31.1%	(3x10 <sup>-31</sup> )	31.3%	(1x10 <sup>-27</sup> )	14.1%	(5x10 <sup>-59</sup> )	13.5%	5x10 <sup>-43</sup> )	
	Multiple Sclerosis	39.3%	(6x10 <sup>-56</sup> )	42.5%	(3x10 <sup>-51</sup> )	16.9%	(5x10 <sup>-54</sup> )	20.0%	(8x10 <sup>-57</sup> )	
Nervous System	Myasthenia Gravis	33.3%	(5x10 <sup>-5</sup> )	29.2%	(3x10 <sup>-2</sup> )	14.1%	(5x10 <sup>-6</sup> )	14.8%	(4x10 <sup>-5</sup> )	
	Coeliac	27.3%	(3x10 <sup>-12</sup> )	29.8%	(2x10 <sup>-12</sup> )	8.4%	(4x10 <sup>-8</sup> )	9.5%	(7x10 <sup>-8</sup> )	
Digestive system	Inflammatory Bowel Disease	24.9%	(6x10 <sup>-11</sup> )	24.9%	(3x10 <sup>-8</sup> )	8.9%	(8x10 <sup>-22</sup> )	9.1%	(2x10 <sup>-17</sup> )	
Skin	Psoriasis	26.8%	(2x10 <sup>-22</sup> )	28.3%	(1x10 <sup>-17</sup> )	8.7%	(4x10 <sup>-20</sup> )	9.9%	(4x10 <sup>-18</sup> )	
	Ankylosing Spondylitis	26.9%	(5x10 <sup>-7</sup> )	28.4%	(5x10 <sup>-4</sup> )	9.6%	(7x10 <sup>-9</sup> )	10.5%	(9x10 <sup>-5</sup> )	
	Polymyalgia Rheumatica/GCA	29.3%	(2x10 <sup>-13</sup> )	27.8%	(5x10 <sup>-6</sup> )	10.8%	(3x10 <sup>-15</sup> )	10.6%	(1x10 <sup>-8</sup> )	
Musculoskeletal system	Psoriatic Arthritis	31.8%	(3x10 <sup>-15</sup> )	34.3%	(5x10 <sup>-16</sup> )	10.2%	(1x10 <sup>-8</sup> )	13.0%	(2x10 <sup>-13</sup> )	
and connective tissue	Rheumatoid Arthritis	30.6%	(5x10 <sup>-62</sup> )	29.4%	(6x10 <sup>-28</sup> )	12.7%	(3x10 <sup>-92</sup> )	12.1%	(1x10 <sup>-45</sup> )	
	Sjögren Syndrome	40.7%	(4x10 <sup>-25</sup> )	41.9%	(1x10 <sup>-17</sup> )	18.9%	(2x10 <sup>-28</sup> )	18.9%	(7x10 <sup>-18</sup> )	
	Systemic Lupus Erythematosus	40.2%	(2x10 <sup>-25</sup> )	44.5%	(2x10 <sup>-22</sup> )	18.8%	(6x10 <sup>-30</sup> )	22.2%	(8x10 <sup>-27</sup> )	

244	The prevalence of possible cases of any autoimmune disease was significantly higher in depression cases
245	compared to depression controls (p = $6x10^{-177}$ for any depression versus controls, p = $3x10^{-207}$ for
246	stringent depression versus controls). The prevalence of probable cases of any autoimmune disease was
247	significantly higher in depression cases compared to depression controls ( $p = 2x10^{-124}$ for any depression
248	versus controls, $p = 6x10^{-163}$ for stringent depression versus controls) (Table 4).

Table 4: Prevalence of autoimmune diseases within depression cases compared to depression controls, stratified by possible/probable for autoimmune diseases, and stringent/any for depression cases. P-values from pairwise comparisons of autoimmune prevalence in depression cases compared to depression controls are shown in brackets.

		Autoimmune prevalence in depression										
		Possible au	toimmune prevale	ence	Probable autoimmune prevalence							
Au	toimmune Trait	Any Depression	Stringent Depression	Depression Controls	Any Depression	Stringent Depression	Depression Controls					
	Any Autoimmune Disease	<b>10.48%</b> (6x10 <sup>-177</sup> )	<b>14.27%</b> (3x10 <sup>-207</sup> )	6.94%	6.59% (2x10 <sup>-124</sup> )	<b>9.48%</b> (6x10 <sup>-163</sup> )	4.19%					
Blood	Pernicious Anemia	0.77% (4x10 <sup>-36</sup> )	1.17% (1x10 <sup>-39</sup> )	0.36%	0.19% (4x10 <sup>-8</sup> )	0.35% (4x10 <sup>-15</sup> )	0.10%					
Fuele eries evetere	Autoimmune Thyroid Disease	0.41% (6x10 <sup>-19</sup> )	0.58% (1x10 <sup>-16</sup> )	0.20%	0.28% (6x10 <sup>-13</sup> )	0.39% (3x10 <sup>-11</sup> )	0.14%					
Endocrine system	Type 1 diabetes	1.20% (3x10 <sup>-31</sup> )	2.07% (5x10 <sup>-59</sup> )	0.69%	1.02% (1x10 <sup>-27</sup> )	1.65% (5x10 <sup>-43</sup> )	0.58%					
	Multiple Sclerosis	0.87% (6x10 <sup>-56</sup> )	1.31% (5x10 <sup>-54</sup> )	0.35%	0.63% (3x10 <sup>-51</sup> )	1.02% (8x10 <sup>-57</sup> )	0.22%					
Nervous System	Myasthenia Gravis	0.11% (5x10 <sup>-5</sup> )	0.17% (5x10⁻6)	0.05%	0.06% (3x10 <sup>-2</sup> )	0.12% (4x10 <sup>-5</sup> )	0.04%					
Disective	Coeliac	0.92% (3x10 <sup>-12</sup> )	1.08% (4x10 <sup>-8</sup> )	0.64%	0.54% (2x10 <sup>-12</sup> )	0.64% (7x10⁻³)	0.33%					
Digestive system	Inflammatory Bowel Disease	1.82% (6x10 <sup>-11</sup> )	2.56% (8x10 <sup>-22</sup> )	1.43%	1.28% (3x10 <sup>-8</sup> )	1.85% (2x10 <sup>-17</sup> )	1.00%					
Skin	Psoriasis	2.05% (2x10 <sup>-22</sup> )	2.55% (4x10 <sup>-20</sup> )	1.46%	1.10% (1x10 <sup>-17</sup> )	1.47% (4x10 <sup>-18</sup> )	0.73%					
	Ankylosing Spondylitis	0.52% (5x10 <sup>-7</sup> )	0.72% (7x10 <sup>-9</sup> )	0.37%	0.17% (5x10 <sup>-4</sup> )	0.25% (9x10⁻⁵)	0.11%					
	Polymyalgia Rheumatica/GCA	0.66% (2x10 <sup>-13</sup> )	0.93% (3x10 <sup>-15</sup> )	0.42%	0.35% (5x10 <sup>-6</sup> )	0.51% (1x10 <sup>-8</sup> )	0.23%					
Musculoskeletal	Psoriatic Arthritis	0.50% (3x10 <sup>-15</sup> )	0.58% (1x10 <sup>-8</sup> )	0.28%	0.38% (5x10 <sup>-16</sup> )	0.51% (2x10 <sup>-13</sup> )	0.19%					
system and connective tissue	Rheumatoid Arthritis	2.66% (5x10 <sup>-62</sup> )	4.14% (3x10 <sup>-92</sup> )	1.59%	1.42% (6x10 <sup>-28</sup> )	2.23% (1x10 <sup>-45</sup> )	0.89%					
	Sjögren Syndrome	0.34% (4x10 <sup>-25</sup> )	0.55% (2x10 <sup>-28</sup> )	0.13%	0.21% (1x10 <sup>-17</sup> )	0.33% (7x10 <sup>-18</sup> )	0.08%					
	Systemic Lupus Erythematosus	0.36% (2x10 <sup>-25</sup> )	0.59% (6x10 <sup>-30</sup> )	0.14%	0.23% (2x10 <sup>-22</sup> )	0.39% (8x10 <sup>-27</sup> )	0.08%					

Testing for same-trait PRS associations, PRS for MDD were significantly associated with any depression case-status ( $p < 5x10^{-324}$ ,  $R^2 = 1.48\%$ ,) and stringent depression case-status ( $p = 2x10^{-228}$ ,  $R^2 = 2.23\%$ ). PRS for autoimmune diseases were significantly associated with both possible and probable case-control status for the corresponding diseases (Figure 2). The variance in liability,  $R^2$ , explained by PRS was higher in strictly-defined compared to liberally-defined phenotypes. Most results were highly significant (p < $6x10^{-29}$ ), except myasthenia gravis ( $p < 7x10^{-3}$ ), which has the smallest sample size of 234 cases, and psoriatic arthritis ( $p < 3 \times 10^{-6}$ ) where the discovery GWAS has only 1430 cases.





Figure 2: Variances in autoimmune liability explained by PRS for the corresponding autoimmune diseases. The number of cases are shown at the top of the plot (possible = blue, probable = red). P-values are shown atop each bar.

Power analyses showed that, in the prediction of any depression from autoimmune PRS, there was 80%
 power to detect associations assuming modest levels of underlying genetic correlation (rG); rG <0.05 for</li>
 coeliac, MS, psoriasis, and SLE; rG <0.1 for IBD, PsA and RA; and rG < 0.17 for MG (Supplementary Figure</li>

medRxiv preprint doi: https://doi.org/10.1101/2020.12.08.20242495; this version posted March 16, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

267 2). In the prediction of possible autoimmune diseases from depression PRS, there was 80% power to 268 detect associations assuming rG < 0.05 for coeliac and IBD; rG < 0.1 for psoriasis and RA; and rG < 0.15 269 for PsA and SLE. There were two exceptions; MS and MG, where the underlying rG would need to 270 approach ~0.3 to achieve 80% power (Supplementary Figure 3).

In the prediction of depression from autoimmune PRS (Figure 3), PRS for myasthenia gravis were significantly associated with case-status for any depression ( $p = 5.2x10^{-5}$ ,  $R^2 = 0.01\%$ ) and stringent depression ( $p = 1.6x10^{-5}$ ,  $R^2 = 0.04\%$ ). PRS for psoriasis were significantly associated with case-status for any depression ( $p = 8.7x10^{-6}$ ,  $R^2 = 0.01\%$ ). No other autoimmune disease PRS predicted depression casecontrol status, and no sex-specific analyses met the Bonferroni-corrected threshold. The  $R^2$  values for variance explained in depression by autoimmune PRS are all very low, at <0.1%, and substantially lower than the  $R^2$  for autoimmune diseases (Figure 2).



278


Figure 3: Variances in depression liability explained by PRS for autoimmune diseases (x-axis). Asterisks denote
associations with p-values < 7.1x10<sup>-5</sup>, meeting Bonferroni correction. Number of cases for depression phenotypes: Any
(combined) = 65,075; Any (female) = 43,413; Any (male) = 21,662; Stringent (combined) = 14,625; Stringent (female) =
9,738; Stringent (male) = 4,887.

283

284 In the prediction of autoimmune diseases from depression PRS, genetic liability for MDD was 285 significantly associated with six autoimmune diseases: coeliac, inflammatory bowel disease, psoriasis, 286 psoriatic arthritis, rheumatoid arthritis, and type 1 diabetes (all p-values  $< 5.8 \times 10^{-5}$ ,  $R^2$  range between 287 0.06% and 0.27%) (Figure 4). For three, the association with MDD was observed in probable and possible 288 cases (psoriasis, rheumatoid arthritis and type 1 diabetes). For coeliac and inflammatory bowel disease, the association was only in possible cases. For psoriatic arthritis, the association was only in probable 289 290 cases. For all significant associations, higher PRS increased risk for the outcome phenotype, except for coeliac, where higher MDD PRS was associated with reduced risk ( $p = 6x10^{-8}$ ,  $R^2 = 0.17\%$ , beta = -0.11, SE 291 292 = 0.02, in the combined sample).

293 In the prediction of autoimmune diseases from depression PRS, sex-specific associations were observed, 294 primarily in female autoimmune cases (coeliac, inflammatory bowel disease, type 1 diabetes and 295 rheumatoid arthritis, all  $p < 4.5 \times 10^{-5}$ ). Association in males was observed in psoriasis (possible cases, p =296 5.8x10<sup>-5</sup>), and in rheumatoid arthritis (possible cases,  $p = 1.6x10^{-5}$ ). The most consistent results were 297 observed in rheumatoid arthritis, where the sample size was largest, with five of the six analyses reaching Bonferroni threshold (all  $p < 4.5 \times 10^{-5}$ ,  $R^2$  range between 0.07% and 0.1%). However, there was no 298 299 evidence for a significant interaction between sex and PRS in the combined samples of men and women 300 (all p > 0.02), indicating that sex-specific associations were generally influenced by sample size.

Full results of each test are shown in Supplementary Tables 3 to 6 and Supplementary Figures 4 to 7.



302

Figure 4: Variances in autoimmune liability (x-axes) explained by PRS for MDD. Asterisks denote associations with p values < 7.1x10<sup>-5</sup>, meeting Bonferroni correction. Number of cases for the autoimmune diseases are given in Table 2.
 305

306	Significant genetic correlations (rG) were observed between inflammatory bowel disease and any
307	depression (rG = 0.11, 95% CI = 0.03 - 0.18, p = $3.8 \times 10^{-3}$ ) and stringent depression (rG = 0.16, 95% CI =
308	0.07 - 0.24, p = 3.0x10 <sup>-4</sup> ); and between psoriasis and stringent depression (rG = 0.16, 95% CI = 0.06 - 0.26,

- $p = 1.1 \times 10^{-3}$ ). No other traits met the Bonferroni-corrected threshold for significance in rG analyses
- 310 (Supplementary Table 7).

#### 311 Discussion

Motivated by epidemiological findings of a bi-directional relationship between depression and autoimmune diseases, we tested for evidence of pleiotropy between traits, adopting both liberal and strict phenotyping to define cases in the UKB. We showed modest association of PRS from autoimmune diseases with MDD, and slightly stronger associations of MDD PRS with autoimmune diseases. These observations suggest only a minor component of observed comorbidity is due to shared genetics between depression and autoimmune diseases.

We made three key observations: 1) Phenotypic variance explained by PRS for corresponding traits was higher in strictly-defined than liberally-defined cases, indicating more rigorous phenotyping improved the validity of autoimmune and depression cases; 2) The phenotypic overlap between depression and autoimmune diseases was consistent with the literature – depression was more common in individuals with autoimmune diseases, and vice-versa; 3) Cross-trait PRS analyses identified significant associations between depression and some autoimmune diseases, but with effect sizes indicating the existence of a shared biological component of modest effect on the observed comorbidity.

Our phenotyping approach used both strictly-defined and liberally-defined cases, integrating the multiple sources of UKB data. PRS for eight autoimmune diseases predicted case-control status, increasing confidence in the robustness of case definition. The phenotypic variance explained was higher in strictly-defined cases, potentially reflecting greater specificity; identifying individuals with multiple endorsements for a disease reduces the probability of misclassifying controls as cases. Conversely, the

criteria for liberally-defined cases increases sample size, but may induce misclassification of controls ascases.

For each of the autoimmune diseases considered, cases had higher frequencies of depression than controls, recapitulating the effect observed in epidemiological studies. Similarly, the prevalence of each autoimmune disease was significantly higher in depression cases compared to controls. Prevalence estimates reported here are cross-sectional, and we lack information on the temporal relationship between traits.

337 Cross-trait PRS analyses identified significant associations, although observed effect sizes were small, ranging between  $R^2$  = 0.01% and 0.27%. Compared with the substantially higher phenotypic variance 338 339 explained by PRS for autoimmune diseases in corresponding traits, the small effect sizes observed in 340 cross-trait PRS analyses provide a useful contrast, indicating only a small contribution of shared genetic influences in the observed comorbidities. However, this was not universally true – MDD PRS captured 341 342 nearly the same amount of variance in probable psoriatic arthritis (0.27%) as the PRS for psoriatic 343 arthritis (0.29%). For all significant associations, higher PRS increased risk for the outcome phenotype. 344 Interestingly, there was one exception, where higher MDD PRS was associated with reduced risk for 345 coeliac disease. This is intriguing given the positive phenotypic correlation between depression and 346 coeliac disease and may warrant further investigation.

For three traits, we observed significant associations in liberally-defined, but not strictly-defined cases (psoriasis PRS was associated with any depression, MDD PRS was associated with possible coeliac and inflammatory bowel disease). In contrast, MDD PRS was associated with probable, but not possible,

psoriatic arthritis, suggesting misclassification in possible cases. Misclassification bias may vary across diseases; some autoimmune diseases may be more prone to misclassification with other autoimmune diseases, whilst other diagnoses may misclassify with non-inflammatory conditions. For example, osteoarthritis (non-inflammatory) may misclassify as psoriatic arthritis in the absence of multiple-item endorsement to increase diagnosis validity.

355 Cross-trait PRS analyses identified some sex-dependent associations. MDD PRS were associated with psoriasis in males, and MDD PRS were associated with coeliac, inflammatory bowel disease and type 1 356 357 diabetes in females. However, sensitivity analyses revealed no evidence for significant interactions 358 between PRS and sex in the combined sample, indicating that sex-dependent associations were generally driven by different sample sizes in sex-stratified analyses. Rheumatoid arthritis was the most common 359 360 autoimmune disease and showed the most consistency in cross-trait associations; MDD PRS were significantly associated with rheumatoid arthritis in all case groups, except probable males. This is in 361 contrast with Euesden, et al.<sup>10</sup>, found no evidence for association between PRS for depression and risk 362 for rheumatoid arthritis, but in a substantially smaller sample of 226 cases. Liu, et al.<sup>6</sup> also found no 363 364 evidence for association between a composite mental health disorder PRS and risk for autoimmune 365 diseases, but also in a smaller sample of 1,383 individuals with any of seven autoimmune diseases. A 366 composite PRS for autoimmune diseases did show weak association with case-control status in a sample of 43,902 individuals with any of six mental health disorders in the Liu, et al.<sup>6</sup> study. This highlights the 367 368 importance of sample size, and our study benefits from the scale of the UKB, where power calculations 369 indicated our investigation was able to detect modest pleiotropic effects.

In contrast to the small, but significant, cross-trait PRS associations observed between depression and several autoimmune diseases, we only observed significant genetic correlations between depression and two autoimmune diseases: inflammatory bowel disease and psoriasis. The PRS methodology, which exploits the use of individual-level data, may have increased power to detect weak genetic effects compared to LDSC, which uses only summary statistics.

375 The weak genetic contribution suggests that another mechanism may be driving or contributing to the bi-directional relationship between autoimmune diseases and depression<sup>44</sup>. Inflammatory factors 376 377 underlying some cases of depression could provide a common biological pathogenesis with autoimmune diseases. Lynall, et al.<sup>45</sup> observed increased immune cell counts in depression cases compared to 378 379 controls, and identified a sub-group of cases with elevated inflammatory markers who presented with 380 more severe depression than uninflamed cases. Environmental risk factors such as BMI and childhood maltreatment increase risk of both depression and autoimmune diseases and would contribute to the 381 bi-directional effect<sup>46,47</sup>. Similarly, some treatments for depression (antidepressants) and autoimmune 382 383 diseases (steroids) are obesogenic and may increase comorbidity. Diagnosis with autoimmune disease 384 increases risk of depression due to psychological factors in adjusting to a chronic disorder and changes 385 in behaviour such as reduced exercise. Health related behaviours that are elevated in depression 386 (smoking, poor diet and reduced physical activity) increase risk for autoimmune diseases. These 387 mechanisms may not be independent of joint genetic contributors. For example, shared inflammatory 388 mechanisms would lead to horizontal pleiotropy, where genetic variants directly affect both disorders, 389 and vertical pleiotropy can arise through environmental risk factors where genetic variation influences 390 one trait through mediation on another trait. The mechanisms underpinning the observed cross-trait

PRS associations may warrant further investigation, potentially using Mendelian Randomization to investigate whether MDD risk alleles have a causal effect on autoimmune diseases, and vice versa. It is also interesting to speculate that associations could be driven by 'phenotypic hitchhiking', in which a GWAS for one trait (e.g. MDD) ascertains patients with comorbid diseases (e.g. autoimmune), potentially inducing cross-trait correlations. Disentangling pleiotropy from 'phenotypic hitchhiking' may warrant further investigation.

#### 397 Limitations

A healthy volunteer bias has been observed in the UKB<sup>48</sup>, and is a noted limitation of the study. However, 398 399 it has been proposed that this bias may attenuate, but not invalidate, exposure-outcome relationships<sup>49</sup>. 400 A further limitation of the ability to extrapolate our results is the lack of representation in individuals of 401 diverse ancestries. The literature has demonstrated attenuation in PRS analyses where training and target samples are drawn from different ancestral populations<sup>50</sup>, highlighting the need to perform GWAS 402 403 in diverse ancestries. This limitation may have broader implications than would otherwise be the case for some conditions, such as SLE, which disproportionately affect individuals of African and Asian 404 405 ancestry.

Although every effort has been made to address the potential for misclassification bias through the criteria for multiple-item endorsements in strictly-defined cases, the approach remains imperfect. For example, limited sample size led to us combine Thyroiditis and Grave's disease, which have opposing thyroid function, under the broader classification of autoimmune thyroid disease.

Despite the scale of the UKB, power calculations showed that for some rare autoimmune diseases, larger samples would be required to reject the presence of a weak genetic correlation with depression. We also observed low SNP-based heritability using published summary statistics for multiple sclerosis, which reduced power to detect pleiotropic effects. The Bonferroni correction applied to cross-trait PRS analyses was conservative since the eight PRS p-value thresholds included in each test of association are correlated, although it is difficult to determine the appropriate correction and we chose to be strict rather than liberal.

# 417 Conclusions

418 We identified cases and controls for depression and fourteen autoimmune diseases in the UKB, using 419 both strict and liberal phenotyping. PRS analyses indicated that strict phenotyping improved the validity 420 of cases, demonstrating that multiple UKB variables can be leveraged to increase specificity. Consistent 421 with the literature, we found that depression was enriched in autoimmune cases, and vice-versa. Despite 422 having power to detect subtle pleiotropic effects, we found little evidence that shared genetic factors 423 have a meaningful influence on the observed co-occurrence of depression and autoimmune diseases in 424 the UK Biobank. The limited shared genetic component will make only a modest contribution to the bi-425 directional disease risks, and shared environmental factors, including health-related characteristics and 426 stressful life events, may be important. Future studies leveraging phenotypic, genetic, diagnostic, 427 treatment and environmental risk factors may be necessary to unpick the mechanisms contributing to 428 shared risks for autoimmune diseases and depression. In particular, future research should consider the

- 429 psychological impacts of autoimmune disease while remaining cognizant of the need to consider and
- 430 treat the two diseases in parallel.

# 431 Funding

This work was supported by the UK Medical Research Council (PhD studentship to KPG; grant MR/N015746/1). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

### 437 Acknowledgements

438 We thank participants and scientists involved in making the UK Biobank resource available 439 (http://www.ukbiobank.ac.uk/). The UKB received ethical approval from the North West - Haydock Research Ethics Committee (reference 16/NW/0274). This study was conducted under application 440 441 number 18177. We thank the research participants and employees of 23andMe for making this work possible. The MDD GWAS summary statistics results from 23andMe were available through a Data 442 443 Transfer Agreement between 23andMe, Inc., and King's College, London. Only summary statistics were 444 shared with no individual level data. 23 and Me participants provided informed consent and participated 445 in the research online. The 23andMe protocol was approved by an external Association for the 446 Accreditation of Human Research Protection Programs accredited Institutional Review Board, Ethical 447 and Independent Review Services. Participants were included in the analysis on the basis of consent 448 status as checked at the time data analyses were initiated. Statistical analyses were carried out on the 449 King's Health Partners High Performance Compute Cluster funded with capital equipment grants from 450 the GSTT Charity (TR130505) and Maudsley Charity (980). We thank Nick Dand, Satveer Mahil and

451 Catherine Smith of King's College London for their contribution in identifying medications used in the 452 treatment of Psoriasis in the UKB.

# 453 Data Code and Availability

- 454 Available from UK Biobank subject to standard procedures (www.ukbiobank.ac.uk). The full GWAS
- 455 summary statistics for the 23andMe discovery data set will be made available through 23andMe to
- 456 qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe
- 457 participants. Please visit <u>https://research.23andme.com/collaborate/#publication</u> for more information
- 458 and to apply to access the data.
- 459 The code used during this study are available at GitHub:
  460 <u>https://github.com/kglanville/pleiotropy\_autoimmune\_depression\_ukb</u>.

# 461 Author contributions

462 Conceptualisation and study design: KPG, CML, JG, PFO. Analysis and manuscript: KPG. Analytical 463 consultation and interpretation: CML, JG, PFO, JRIC. UKB data curation and management: JRIC, KPG. 464 Genetic data preparation: JRIC, KPG. Project supervisors: CML, JG, PFO. All authors critically edited the 465 paper.

### 466 Declaration of Interest

467 CML is a member of the SAB for Myriad Neuroscience. The remaining authors declare no competing468 interests.

# 469 References

- Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al.
   Autoimmune Diseases and Severe Infections as Risk Factors for Mood Disorders A
   Nationwide Study. JAMA Psychiatry. American Medical Association; 2013
   Aug;70(8):812–20.
- Anderson RJ, Freedberg KA, Clouse RE, Lustman PJ. The Prevalence of Comorbid
   Depression in Adults With Diabetes. Diabetes Care. 2001 Jun;24(6):1069–78.
- 476 3. Patten SB, Beck CA, Williams JVA, Barbui C, Metz LM. Major depression in multiple
  477 sclerosis: A population-based perspective. Neurology. 61st ed. 2003 Dec;:1524–7.
- 4. Kurina L, Goldacre M, Yeates D, Gill L. Depression and anxiety in people with
  inflammatory bowel disease. Journal of Epidemiology and Community Health. BMJ
  Publishing Group; 2001 Oct 1;55(10):716–20.
- Andersson NW, Gustafsson LN, Okkels N, Taha F, Cole SW, Munk-Jorgensen P, et al.
  Depression and the risk of autoimmune disease: a nationally representative, prospective
  longitudinal study. Psychol Med. Cambridge University Press; 2015 Dec;45(16):3559–
  69.
- 485 6. Liu X, Nudel R, Thompson WK, Appadurai V, Schork AJ, Buil A, et al. Genetic factors 486 underlying the bidirectional relationship between autoimmune and mental disorders – 487 findings from a Danish population-based study. Brain, Behavior, and Immunity.
  488 Academic Press; 2020 Jun 11.
- 489 7. Glanville KP, Coleman JRI, Hanscombe KB, Euesden J, Choi SW, Purves KL, et al.
  490 Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly
  491 Associated With Depression. Biological Psychiatry. Elsevier; 2020 Mar 1;87(5):419–30.
- Nudel R, Benros ME, Krebs MD, Allesøe RL, Lemvigh CK, Bybjerg-Grauholm J, et al.
   Immunity and mental illness: findings from a Danish population-based immunogenetic study of seven psychiatric and neurodevelopmental disorders. European Journal of Human Genetics. Nature Publishing Group; 2019 Apr 11;8(1):1.
- 496 9. Hu X, Daly M. What have we learned from six years of GWAS in autoimmune diseases,
  497 and what is next? Current Opinion in Immunology. Elsevier Current Trends; 2012 Oct
  498 1;24(5):571–5.
- 499 10. Euesden J, Danese A, Lewis CM, Maughan B. A bidirectional relationship between
  500 depression and the autoimmune disorders New perspectives from the National Child
  501 Development Study. PLOS ONE. Public Library of Science; 2017 Mar;12(3):1–14.

- Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al.
   Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics. Nature Publishing Group; 2018
   May;50:668–81.
- Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Han
   B, Wu Y, Mignot E, Ollila HM, et al. Cross-disorder analysis of schizophrenia and 19
   immune-mediated diseases identifies shared genetic risk. Human Molecular Genetics.
   2019 Jun 18.
- Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
   resource with deep phenotyping and genomic data. Nature. Nature Publishing Group;
   2018 Oct 1;562(7726):203–9.
- 513 14. World Health Organization. International Classification of Diseases (10th Edition).
   514 Geneva: World Health Organisation; 1992.
- 515 15. Davis KAS, Coleman JRI, Adams M, Allen N, Breen G, Cullen B, et al. Mental health in
  516 UK Biobank development, implementation and results from an online questionnaire
  517 completed by 157 366 participants: a reanalysis. BJPsych Open. Cambridge University
  518 Press; 2020 Mar 1;6(2):e18.
- 519 16. Glanville KP, Coleman JRI, Howard DM, Pain O, Hanscombe KB, Jermy B, et al.
  520 Multiple measures of depression to enhance validity of major depressive disorder in the 521 UK Biobank. BJPsych Open. Cambridge University Press; 2021 Mar 1;7(2):82.
- 522 17. Smith DJ, Nicholl BI, Cullen B, Martin D, UI-Haq Z, Evans J, et al. Prevalence and
  523 Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank:
  524 Cross-Sectional Study of 172,751 Participants. Potash JB, editor. PLOS ONE. 2013 Nov
  525 25;8(11):e75362.
- 18. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
   PLINK: rising to the challenge of larger and richer datasets. GigaScience [Internet]. 2015
   Feb 25;4(1):559. Available from: www.cog-genomics.org/plink/1.9/
- 529 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen W-M. Robust
  530 relationship inference in genome-wide association studies. Bioinformatics. 2010 Nov
  531 15;26(22):2867–73.
- 532 20. Choi SW. choishingwan/GreedyRelated: Function update. 2020 Mar 4.
- Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank scale genotype datasets. Bioinformatics. 2017 Sep 1;33(17):2776–8.

- R Development Core Team. R: A language and environment for statistical computing
   [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2008. Available from:
   http://www.R-project.org
- Dubois PCA, Trynka G, Franke L, Hunt KA, Romanos J, Curtotti A, et al. Multiple
  common variants for celiac disease influencing immune gene expression. Nature
  Genetics. Nature Publishing Group; 2010 Apr 1;42(4):295–302.
- Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, et al. Association
  analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight
  shared genetic risk across populations. Nature Genetics. Nature Publishing Group; 2015
  Sep 1;47(9):979–86.
- The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case
  Control Consortium 2. Genetic risk and a primary role for cell-mediated immune
  mechanisms in multiple sclerosis. Nature. Nature Publishing Group; 2011 Aug
  1;476(7359):214–9.
- Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, et al. A GenomeWide Association Study of Myasthenia Gravis. JAMA neurology. JAMA Neurol; 2015 Apr
  1;72(4):396–404.
- Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
  meta-analysis characterizes genetic architecture for common psoriasis associated
  variants. Nature Communications. Nature Publishing Group; 2017 May 24;8(1):1–8.
- Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, et al. Genetic
  variation at the glycosaminoglycan metabolism pathway contributes to the risk of
  psoriatic arthritis but not psoriasis. Annals of the Rheumatic Diseases. BMJ Publishing
  Group Ltd; 2019 Mar 1;78(3):355–64.
- 559 29. Okada Y, Di Wu, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis
  560 contributes to biology and drug discovery. Nature. Nature Publishing Group; 2014 Feb
  561 1;506(7488):376–81.
- 30. Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW, et al.
  Genetic association analyses implicate aberrant regulation of innate and adaptive
  immunity genes in the pathogenesis of systemic lupus erythematosus. Nature Genetics.
  Nature Publishing Group; 2015 Dec 1;47(12):1457–64.
- 566 31. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.
  567 PubMed NCBI. GigaScience. 2019 Jul 15;8(7):2091.
- Andres E, Serraj K. Optimal management of pernicious anemia. Journal of blood
   medicine. J Blood Med; 2012;3:97–103.

- Simmonds MJ, Gough SCL. Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clinical and Experimental Immunology. WileyBlackwell; 2004 Apr 1;136(1):1–10.
- 34. Bradfield JP, Qu H-Q, Wang K, Zhang H, Sleiman PM, Kim CE, et al. A Genome-Wide
  Meta-Analysis of Six Type 1 Diabetes Cohorts Identifies Multiple Associated Loci.
  McCarthy MI, editor. PLoS Genet. Public Library of Science; 2011 Sep
  29;7(9):e1002293.
- 577 35. Spillane J, Higham E, Kullmann DM. Myasthenia gravis. BMJ. British Medical Journal 578 Publishing Group; 2012 Dec 21;345(dec21 3):e8497–7.
- Tsoi LC, Stuart PE, Tian C, Gudjonsson JE, Das S, Zawistowski M, et al. Large scale
  meta-analysis characterizes genetic architecture for common psoriasis associated
  variants. PubMed NCBI. Nature Communications. 2017 May 24;8:15382.
- International Genetics of Ankylosing Spondylitis Consortium (IGAS). Identification of
   multiple risk variants for ankylosing spondylitis through high-density genotyping of
   immune-related loci. Nature Genetics. Nature Publishing Group; 2013 Jul 1;45(7):730–8.
- 38. Partington RJ, Muller S, Helliwell T, Mallen CD, Sultan AA. Incidence, prevalence and
  treatment burden of polymyalgia rheumatica in the UK over two decades: a populationbased study. Annals of the Rheumatic Diseases. BMJ Publishing Group Ltd; 2018 Dec
  1;77(12):1750–6.
- Humphreys JH, Verstappen SMM, Hyrich KL, Chipping JR, Marshall T, Symmons DPM.
  The incidence of rheumatoid arthritis in the UK: comparisons using the 2010
  ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from
  the Norfolk Arthritis Register. Annals of the Rheumatic Diseases. BMJ Publishing Group
  Ltd; 2013 Aug 1;72(8):1315–20.
- 40. Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, et al. Variants at
  multiple loci implicated in both innate and adaptive immune responses are associated
  with Sjögren's syndrome. Nature Genetics. Nat Genet; 2013 Oct 6;45(11):1284–92.
- 41. Rees F, Doherty M, Grainge M, Davenport G, Lanyon P, Zhang W. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Annals of the
  83. Rheumatic Diseases. BMJ Publishing Group Ltd; 2016 Jan 1;75(1):136–41.
- Luigi Palla FD. A Fast Method that Uses Polygenic Scores to Estimate the Variance
   Explained by Genome-wide Marker Panels and the Proportion of Variants Affecting a
   Trait. Am J Hum Genet. Elsevier; 2015 Aug 6;97(2):250–9.
- 43. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working
   Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes

- confounding from polygenicity in genome-wide association studies. Nature Genetics.
  2015 Mar;47(3):291–5.
- Gold SM, Köhler-Forsberg O, Moss-Morris R, Mehnert A, Miranda JJ, Bullinger M, et al.
   Comorbid depression in medical diseases. Nat Rev Dis Primers. Nature Publishing
   Group; 2020 Aug 20;6(1):1–22.
- 45. ME L, L T, J B, J C, de Boer P, Mondelli V, et al. Peripheral Blood Cell-Stratified
  Subgroups of Inflamed Depression. Biological Psychiatry. Biol Psychiatry; 2020 Jul
  15;88(2):185–96.
- 46. Dube SR, Fairweather D, Pearson WS, Felitti VJ, Anda RF, Croft JB. Cumulative
  Childhood Stress and Autoimmune Diseases in Adults. Psychosomatic Medicine. 2009
  Feb;71(2):243–50.
- 47. Hughes K, Bellis MA, Hardcastle KA, Sethi D, Butchart A, Mikton C, et al. The effect of
  multiple adverse childhood experiences on health: a systematic review and metaanalysis. The Lancet Public Health. Elsevier; 2017 Aug 1;2(8):e356–66.
- 48. A F, TJ L, C S, N D, L A, T S, et al. Comparison of Sociodemographic and HealthRelated Characteristics of UK Biobank Participants With Those of the General
  Population. American Journal of Epidemiology. Am J Epidemiol; 2017 Nov
  1;186(9):1026–34.
- 49. Batty GD, Gale C, Kivimaki M, Deary I, Bell S. Generalisability of Results from UK
  Biobank: Comparison With a Pooling of 18 Cohort Studies. medRxiv. Cold Spring Harbor
  Laboratory Press; 2019 Aug 13;:19004705.
- 50. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of
   polygenic risk score usage and performance in diverse human populations. Nature
   Communications. Nature Publishing Group; 2019 Jul 25;10(1):1–9.